(Q36979302)

17 August 2017

1 reference

title

Role of platinum agents in the management of advanced pancreatic cancer (English)

1 reference

17 August 2017

1 reference

Muhammad Wasif Saif

1

1 reference

PubMed ID

17956194

17 August 2017

Richard Kim

series ordinal

2

1 reference

PubMed ID

17956194

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

16

1 reference

17 August 2017

2719-2727

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.16.2719

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002093.PUB2

Identifiers

DOI

10.1517/14656566.8.16.2719

1 reference

17 August 2017

1 reference

PubMed ID

17956194